OBJECTIVE: Although platinum-based chemotherapy is widely used in malignant pleural
mesothelioma, its modest therapeutic effect warrants identification of enhancing agents. As …

OBJECTIVE: The phosphoinositide-3 kinase signaling pathway is implicated in the
development of malignancy and promotes cell-cycle progression and resistance to …

Abstract Background and Objectives: Malignant mesothelioma has a poor prognosis and is
refractory to many agents. The antitumor effectiveness of cisplatin, paclitaxel, and suramin …

OBJECTIVE: Optimizing the multimodality treatment of malignant pleural mesothelioma
depends on many factors including an adequate chemotherapeutic response. Currently …

BACKGROUND In a previous FONICAP trial, the combination of doxorubicin (D) and
cisplatin (P) yielded an objective response rate of 25% and a subjective response rate of …

Introduction Human malignant pleural mesothelioma (MPM) is an asbestos-related
malignancy characterized by frequent resistance to chemotherapy and radiotherapy. Here …

Introduction The PI3K/Akt/mammalian target of rapamycin pathway is activated in a majority
of malignant pleural mesotheliomas (MPM). We evaluated the activity of everolimus, an oral …

Malignant pleural mesothelioma (MPM) is an aggressive malignancy for which there is no
approved targeted therapy. We examined the therapeutic efficacy of the mitogen-activated …

BACKGROUND The purpose of this study was to assess the efficacy and toxicity of a
combination of cisplatin and irinotecan (CPT‐11) in the treatment of patients with malignant …

PURPOSE: We performed a phase II study of combined cisplatin 100 mg/m2, given
intravenously on day 1, and gemcitabine 1,000 mg/m2, given intravenously on days 1, 8 …